Pharmaceutical manufacturer scaling clinical operations and cloud infrastructure
Pfizer operates a global pharmaceutical manufacturing and clinical development organization with over 10,000 employees across 25+ countries. The tech stack reveals dual operational tracks: enterprise systems (SAP, Salesforce, Veeva Engage) for commercial and regulatory workflows, paired with cloud infrastructure (AWS, GCP, Azure) and orchestration tooling (Kubernetes, Terraform, Helm) that signal scaling of data pipelines and ML workflows. Active adoption of RAG, Python, and FinOps indicates a shift toward AI-assisted research and cost optimization in cloud spend—priorities that align with stated pain points around clinical procedure efficiency, data quality, and budget control.
Notable leadership hires: Business Lead, PMS Operations Lead, Medical Affairs Lead, Accessibility Solution Lead, Marketing Head
Pfizer manufactures pharmaceuticals and develops clinical assets for global healthcare markets. The company structures operations across sales (553 active roles), marketing (231), healthcare delivery (219), and engineering (193), supported by research (159) and manufacturing (88) teams. Current hiring velocity is steady across all regions, with particular concentration in the United States, China, and Western Europe. Active projects span new product launches, clinical trial support, protocol design, and portfolio strategy—reflecting both commercial and R&D phases of the product lifecycle. Stated challenges center on clinical procedure efficiency, data quality assurance, GCP compliance, and patient engagement.
Pfizer operates across AWS, GCP, and Azure, with infrastructure-as-code tooling including Terraform, Helm, Pulumi, and AWS CDK. The company is actively adopting Terraform and FinOps practices, indicating consolidation of multi-cloud spend.
Current projects include new product launches, clinical trial support, protocol design development, field medical content strategy, clinical procedure optimization, and portfolio strategy work. Cost improvement and early-stage asset development are also active priorities.
Other companies in the same industry, closest in size